Brief: Epigenomics AG Expects Adj Ebitda In Range Of Eur ‑11.0 Mln To Eur ‑11.6 Mln For FY 22
20/03/2023 19:24
March 20 (Reuters) - Epigenomics Ag ECX1k.DE :
* EQS-ADHOC: EPIGENOMICS AG: ADJUSTMENT OF GUIDANCE AND
NOTICE OF
LOSS PURSUANT TO SEC. 92 PARA. 1 OF THE GERMAN STOCK CORPORATION
ACT
* REVENUE FORECAST AND EXPECTED CASH CONSUMPTION-RATE FOR
2022
REMAIN UNCHANGED
* EPIGENOMICS - EXPECTS FOR FINANCIAL YEAR 2022 AN ADJUSTED
EBITDA
(BEFORE SHARE-BASED PAYMENT EXPENSES) IN RANGE OF EUR -11.0
MILLION TO EUR -11.6 MILLION
* EPIGENOMICS - ASSUMED THAT A CUMULATIVE LOSS OF MORE THAN
HALF
OF NOMINAL SHARE CAPITAL OF COMPANY HAS BEEN INCURRED
* LOSS IS MAINLY ATTRIBUTABLE TO BUDGETED LOSSES AND
EXPENSES FROM
RESTRUCTURING MEASURES ANNOUNCED ON FEBRUARY 15, 2023
* NOTIFICATION OF LOSS WILL BE MADE TO THIS YEAR'S ANNUAL
GENERAL
MEETING OF COMPANY, WHICH IS SCHEDULED FOR JUNE
Source text for Eikon: ID:nEQ5X0MJa
Further company coverage: ECX1k.DE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns